Treatment News

/Treatment News

Latest Treatment News in Neuroendocrine Tumours

LUTATHERA® Funded in Ontario

Radiopharmaceutical cancer treatment Lutathera® now available to Ontario patients with midgut neuroendocrine tumours (NETs). The Ontario funding criteria covers the treatment of adult patients with somatostatin receptor-positive (SSR+) midgut NETs [...]

By | 2020-10-10T14:14:05+00:00 October 10th, 2020|Treatment News|Comments Off on LUTATHERA® Funded in Ontario

LUTATHERA® Funded in Quebec

As of September 30, 2020, the Québec Ministry of Health and Social Services has listed Lutathera on the Liste de Médicaments – Établissements. Lutathera will be reimbursed for GEP-NETs patients [...]

By | 2020-10-03T15:46:51+00:00 October 3rd, 2020|Treatment News|Comments Off on LUTATHERA® Funded in Quebec

LUTATHERA® Funded in Nova Scotia

As of August 1, 2020, patients with midgut, GEP-NETs will now be eligible for treatment with LUTATHERA® [lutetium (177Lu) oxodotreotide]. This listing covers adult patients with somatostatin receptor-positive (SSR+) midgut [...]

By | 2020-09-06T16:03:58+00:00 September 4th, 2020|Treatment News|Comments Off on LUTATHERA® Funded in Nova Scotia

New Delivery System for Somatuline® Autogel®

Ipsen Announces the Availability of the Newly Designed Delivery System for Somatuline® Autogel® (lanreotide injection) Ipsen Biopharmaceuticals Canada Inc. today announced the availability of a new delivery system for [...]

By | 2020-01-07T23:48:51+00:00 January 7th, 2020|Treatment News|Comments Off on New Delivery System for Somatuline® Autogel®

68Ga-DOTATATE PET scan in Ontario

68Ga-DOTATATE PET scan in Ontario Cancer Care Ontario has announced that as of April 1st, 2019, Ontario patients with neuroendocrine tumours (NETs) meeting eligibility criteria are able to have [...]

By | 2019-04-12T23:00:13+00:00 April 12th, 2019|Treatment News|Comments Off on 68Ga-DOTATATE PET scan in Ontario

Health Canada approves XERMELO™ (telotristat ethyl)

Health Canada approves XERMELO™ (telotristat ethyl) for the treatment of adult patients suffering from refractory carcinoid syndrome diarrhea(1) "XERMELOTM is a novel, orally administered, inhibitor of the enzyme tryptophan hydroxylase [...]

By | 2018-10-17T14:45:09+00:00 October 17th, 2018|Treatment News|Comments Off on Health Canada approves XERMELO™ (telotristat ethyl)

Public Listings for Caprelsa

Caprelsa (vandetanib) is indicated for the treatment of symptomatic or progressive Medullary thyroid cancer in adult patients with unresectable locally advanced or metastatic disease. Alberta Health Services has put the [...]

By | 2018-09-18T23:32:14+00:00 September 18th, 2018|Treatment News|Comments Off on Public Listings for Caprelsa

Patient Input – Treatment with Telotristat

TELOTRISTAT is an adjunct to somatostatin analogue therapy for the long-term treatment of carcinoid syndrome to improve symptom control in adult patients with metastatic neuroendocrine tumours.The company who makes telotristat [...]

By | 2018-09-03T18:47:17+00:00 September 3rd, 2018|Survey, Treatment News|Comments Off on Patient Input – Treatment with Telotristat

Health Canada approves Ipsen’s Somatuline® Autogel® for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumours (NETs)

Somatuline Autogel is the first and only somatostatin analog (SSA) approved in Canada to treat enteropancreatic neuroendocrine tumours and carcinoid syndrome. Februaury 13th, 2018 - Health Canada announced the approval [...]

By | 2018-05-07T18:28:10+00:00 February 13th, 2018|Treatment News|Comments Off on Health Canada approves Ipsen’s Somatuline® Autogel® for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumours (NETs)